Pfizer Bolsters Anti-Infectives Presence with Basilea Deal
By Natasha Piper
Pharma Deals Review: Vol 2017 Issue 6 (Table of Contents)
Published: 30 Jun-2017
DOI: 10.3833/pdr.v2017.i6.2259 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Basilea Pharmaceutica has licensed rights to its antifungal drug, Cresemba® (isavucanazole), to Pfizer in Europe (excluding Nordic countries), Russia, Turkey and Israel for US$72 M upfront and up to US$427 M in milestone payments...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS